about
DNA and the chromosome - varied targets for chemotherapyEvolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signalZeb1 links epithelial-mesenchymal transition and cellular senescenceRole of protein tyrosine phosphatases in cancerModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesHDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.Global analysis of gene expression changes during retinoic acid-induced growth arrest and differentiation of melanoma: comparison to differentially expressed genes in melanocytes vs melanomaSuccessful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsA phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma GroupNovel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytesmiR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemiaEpigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosisRUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines.Azacitidine.Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesDNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells.Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation.Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.Increased mitochondrial DNA copy number in occupations associated with low-dose benzene exposure.The silence of the genes: epigenetic disturbances in haematopoietic malignancies.5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis.Epigenetic changes in virus-associated human cancers.Causes and consequences of DNA hypomethylation in human cancer.5-azacytidine and decitabine monotherapies of myelodysplastic disorders.Lung epithelium as a sentinel and effector system in pneumonia--molecular mechanisms of pathogen recognition and signal transductionThe novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cellsGene silencing by DNA methylation in haematological malignancies.Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes.Transcription factors as therapeutic targets in lymphoid malignancies.Chromatin condensation in terminally differentiating mouse erythroblasts does not involve special architectural proteins but depends on histone deacetylation.Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis
P2860
Q24792540-66DA19E5-B557-4745-B86E-5BD40E827C6DQ26745566-4F59272F-059E-4E55-B8E1-91BB8AE74136Q28384242-D828D4F4-82B6-4F11-AD9B-2A156A4D194DQ28508357-46FDE7BE-05ED-4EC5-A01E-893816F48FB8Q28741003-0EBE9BAD-A878-480A-B2A8-481D961E8C7DQ30570945-990CDDEF-B9B5-4705-92F4-A2F6114E5804Q33344484-34F5905D-9245-49B2-8C73-57F63D0E5A56Q33375218-AD1EEF56-6C69-4318-94AE-EE90E4281896Q33407141-42C4AB88-7547-4D3A-A034-0A4EA0C21906Q33409579-74D8E536-C85D-4B51-AB41-18155D9FD440Q33728336-8260F94A-4E7F-4387-8CA0-34CB1AF8A1B2Q33772607-74509025-7ED3-4300-948C-ED79A9C80381Q33784496-8E020A64-5CC4-4F2B-BEE8-498F2D25CA8EQ33982491-ECC54DF1-F434-4FCE-9475-13405657D31BQ34087012-68B5D68B-5AD3-4B5B-A778-A47EB4121058Q34104638-E5B0C577-F065-44EC-BD53-2BC470D7C927Q34414813-B8A783FB-CD16-4333-AFF2-75D1B8993182Q34528296-3A9F39AA-CE2E-44B6-977C-BBA1082D890AQ34768789-1AE58B34-DD15-4415-9F1C-49D0F095D30EQ35011903-9C6D9C8D-E956-49C3-BFDA-635D8F585191Q35109954-BA69D1E0-BBE3-4201-A7E7-53931F419FF2Q35235267-5BBF060F-3895-43D4-88B0-20DDFBB389BEQ35741571-BD33CC7A-9803-462A-97CF-7177B13445F3Q35756870-2F639B8C-4778-4CB5-898F-277BE8F7400AQ36066276-CD07FB3D-A321-44E7-BA1A-68CC3AC1F248Q36089887-4581F6C9-6B3F-468F-8DD2-9B19BB3886F8Q36109306-F89AE827-32D2-4EB6-AA79-86D46556E5A5Q36164751-AA81554F-F33A-413E-A78D-206FBF9DC390Q36250201-BA84DEC3-2536-40F5-AA2E-DA5785D21083Q36530445-D8C70529-2641-431C-BF95-9350F1E33922Q36658033-A0F365F4-8F1B-4989-BBE5-EA0A16C14A28Q36816162-355A1F43-D804-4A0D-81D7-E7745E45F260Q36871702-29B8FA0C-1F77-4C84-BEA4-A68CC413F1BDQ37008654-C140E3C0-540F-40B5-8C97-4A5CA0E99686Q37155979-A6A4B5A9-B9A9-4D2F-AA64-46020C2BA7B0Q37184917-3F31A3F9-F7CC-401F-8F45-A14B3297C342Q37211663-454DDCBA-6FE6-4A12-8AD9-540403196832Q37324449-1C3A9260-A0FB-4181-BD1D-A8943F130D40Q37333839-088E2EA8-3A60-40DD-9F99-32B3D8C8B220Q37354193-0A7B5B42-4517-4E0F-A323-5F1C03DE03FB
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Epigenetic targets in hematopoietic malignancies.
@ast
Epigenetic targets in hematopoietic malignancies.
@en
type
label
Epigenetic targets in hematopoietic malignancies.
@ast
Epigenetic targets in hematopoietic malignancies.
@en
prefLabel
Epigenetic targets in hematopoietic malignancies.
@ast
Epigenetic targets in hematopoietic malignancies.
@en
P2860
P356
P1433
P1476
Epigenetic targets in hematopoietic malignancies.
@en
P2093
Michael Lübbert
Rainer Claus
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206814
P407
P577
2003-09-01T00:00:00Z
P5875
P6179
1025860592